OVERVIEW

Live Webinar: Part 2 - Expert Perspectives on Practice-Changing Strategies for Improved Patient Outcomes in Multiple Myeloma is organized by i3 Health and will be held on Jan 18, 2022.

Target Audience:
Hematologists, oncologists, nurse practitioners, physician assistants, and other health care professionals involved in the treatment of patients with multiple myeloma (MM).

Statement of Need:
Multiple myeloma is a B-cell neoplasm characterized by expansion of plasma cells within the bone marrow and extramedullary sites (ACS, 2021). For patients who relapse, treatment becomes increasingly complex, and outcomes worsen with each relapse (Siegal et al, 2020). Advanced multiple myeloma may be associated with considerable disease-related comorbidities in addition to treatment-related adverse events and impaired quality of life, all of which increase the challenges of treatment planning (Gegenback et al, 2021). Therapeutic options for relapsed/refractory multiple myeloma are rapidly changing with evolving data, making it difficult for clinicians to stay abreast of the latest advances in multiple myeloma treatment (i3 Health, 2021). In this webinar, Sarah Holstein, MD, PhD, and Ashley Rosko, MD, will familiarize practitioners with indications of multiple myeloma progression and timing of therapy, highlight practice-changing trials in the early and late relapse settings, and discuss how their approaches to relapsed/refractory multiple myeloma are changing based on emerging data.

Learning Objectives:
Upon completion of this activity, participants should be able to:
• Differentiate biochemical versus clinical relapse and indications for the treatment of multiple myeloma progression
• Appraise emerging efficacy and safety data on novel combination therapies for early relapse in patients with multiple myeloma
• Appraise emerging efficacy and safety data on novel combination therapies for late relapse in patients with multiple myeloma

Faculty:
• Sarah A. Holstein, MD
Associate Professor
Division of Oncology and Hematology
Univeristy of Nebraska Medical Center

• Ashley E. Rosko, MD
Associate Professor of Medicine
Medical Director of Oncogeriatrics
The Ohio State University
The James Comprehensive Cancer Center

This two-part live webinar series led by Sarah A. Holstein, MD, PhD, and Ashley E. Rosko, MD, will explore expert perspectives on practice-changing developments in the management of multiple myeloma and will also include updates from the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition.

Part 2 will familiarize practitioners with indications of multiple myeloma progression and timing of therapy, highlight practice-changing trials in the early and late relapse settings, and discuss how approaches to relapsed/refractory multiple myeloma are changing based on emerging data.